Exhibit 23.1

KPMG LLP 600 de Maisonneuve Blvd. West Suite 1500, Tour KPMG Montréal (Québec) H3A 0A3 Canada

Telephone Fax Internet

(514) 840-2100 (514) 840-2187 www.kpmg.ca

Consent of Independent Registered Public Accounting Firm

The Board of Directors

Acasti Pharma Inc.:

We consent to the use of our report dated June 29, 2020, with respect to the consolidated balance sheets as of March 31, 2020 and 2019 of Acasti Pharma Inc., the related consolidated statements of loss and comprehensive loss, changes in shareholders' equity and cash flows for each of the years in the two-year period ended March 31, 2020, and the related notes, incorporated by reference herein and to the reference to our firm under the heading “Experts” in the prospectuses.

The audit report dated June 29, 2020 contains an explanatory paragraph that states that Acasti Pharma Inc. has incurred operating losses and negative cash flows from operations since its inception, and additional funds will be needed in the future that raise substantial doubt about its ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

The audit report dated June 29, 2020 also refers to a change in accounting framework as Acasti Pharma Inc. has retrospectively adopted U.S. generally accepted accounting principles and has changed its reporting currency from Canadian dollars to U.S. dollars.

/s/ KPMG LLP*

June 29, 2020

Montréal, Canada

*CPA auditor, CA, public accountancy permit No. A122596